利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.022 秒)

    Flavivirus vaccine
    1.
    发明授权
    Flavivirus vaccine 有权

    公开(公告)号：US11931406B2

    公开(公告)日：2024-03-19

    申请号：US16772131

    申请日：2018-12-12

    申请人： CureVac SE ,  Sanofi Pasteur

    发明人： Patrick Baumhof ,  Wolfgang Grosse ,  Edith Jasny ,  Thomas Kramps ,  Daniel Voss ,  Julia Dannenmaier ,  Valérie Lecouturier ,  Yves Girerd-Chambaz

    IPC分类号： A61K39/12 ,  A61P31/14 ,  A61K39/00

    CPC分类号： A61K39/12 ,  A61P31/14 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/6031 ,  C12N2770/24134

    摘要： The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

    Zika virus vaccine
    2.
    发明授权
    Zika virus vaccine 有权

    公开(公告)号：US11723967B2

    公开(公告)日：2023-08-15

    申请号：US15999469

    申请日：2017-02-17

    申请人： CureVac SE ,  Sanofi Pasteur

    发明人： Benjamin Petsch ,  Edith Jasny ,  Yves Girerd-Chambaz

    IPC分类号： A61K39/12 ,  A61K47/64 ,  A61P31/14 ,  A61K39/385 ,  C07K14/005

    CPC分类号： A61K39/12 ,  A61K39/385 ,  A61K47/646 ,  A61K47/6455 ,  A61P31/14 ,  C07K14/005

    摘要： The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

    INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS
    5.
    发明申请
    INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS 审中-公开
    诱导针对RHNVIRUS抗原的交叉反应性细胞反应

    公开(公告)号：US20160095916A1

    公开(公告)日：2016-04-07

    申请号：US14766268

    申请日：2014-02-06

    申请人： SANOFI PASTEUR ,  IMPERIAL INNOVATIONS LIMITED

    发明人： Gary McLean ,  Walton Ross ,  Sebastian Johnson ,  Nathan Bartlett ,  Bruno Guy ,  Yves Girerd-Chambaz ,  Valerie Lecouturier ,  Jeffrey Almond ,  Nicholas Glanville ,  Nicolas Burdin

    IPC分类号： A61K39/125

    CPC分类号： A61K39/125 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N9/127 ,  C12N2770/32722 ,  C12N2770/32734

    摘要： The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.

    摘要翻译： 本发明涉及：a）分离的肽，其包含与鼻病毒的VP4氨基酸序列至少90％相同的氨基酸序列，或包含编码所述肽的核酸序列的分离的多核苷酸，其置于 其在哺乳动物细胞中表达所必需的元素; 和/或b）分离的肽，其包含至少100个氨基酸的氨基酸序列，其与位于鼻病毒RNA聚合酶的最后363个C末端氨基酸中的氨基酸序列至少90％相同，或 分离的多核苷酸，其包含编码所述肽的核酸序列，置于其在哺乳动物细胞中表达所必需的元件的控制下; 和c）当所述免疫原性组合物包含一种或多种所述分离的肽时，Th1佐剂。

    Compositions for booster vaccination against dengue
    7.
    发明授权
    Compositions for booster vaccination against dengue 有权

    公开(公告)号：US11690903B2

    公开(公告)日：2023-07-04

    申请号：US16652902

    申请日：2018-10-05

    申请人： Sanofi Pasteur

    发明人： Diana Coronel ,  Betzana Zambrano ,  Fernando Noriega ,  Tram Anh Wartel ,  Yves Girerd-Chambaz

    IPC分类号： A61K39/12 ,  A61P31/14 ,  A61K39/00

    CPC分类号： A61K39/12 ,  A61P31/14 ,  A61K2039/545 ,  A61K2039/70

    摘要： The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue naïve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4. The invention is also directed to a method of inducing in a human subject a neutralizing antibody response comprising the administration of a vaccine composition, or to a vaccine composition for use in such a method, said composition comprising a dengue antigen of each of serotypes 1 to 4, or a nucleic acid construct capable of expressing in said subject a dengue antigen of each of serotypes 1 to 4; wherein said composition is administered as a primary vaccination, followed by a booster vaccination, and wherein the human subject is initially dengue naïve.